Phase 4 Atrial Fibrillation Trial, Recruiting NCT05829317 Sponsor: Dr. Stephanie Sibley Condition: Atrial Fibrillation
Back to Atrial Fibrillation

Phase 4 Atrial Fibrillation Trial, Recruiting

NCT05829317
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older
  • People who have been admitted to an intensive care unit (ICU) and are receiving breathing support through a mask or high-flow oxygen, or are on a breathing machine, where that support is expected to last more than 24 hours due to breathing difficulties
  • People in the ICU who are receiving medications to support their blood pressure or heart function, where that support is expected to last more than 24 hours
  • People who have been admitted to the ICU following a cardiac arrest (when the heart stops beating)
  • People who are having their heart rhythm continuously monitored

Who may not be able to join:

  • People who have already been receiving ICU breathing or heart support treatments for more than 18 hours before enrolling
  • People who are on a breathing machine solely to keep their airway safe, such as after a head injury, rather than for breathing failure
  • People who have an irregular heart rhythm called atrial fibrillation at the time of enrolment
  • People who are currently taking a heart medication called Amiodarone, either as tablets or through a continuous drip
  • People who are not expected to survive more than 24 hours, or who are receiving palliative (comfort-focused) care
  • People who have had cardiac (heart) surgery
  • People who need magnesium given through a drip or injection for conditions such as pre-eclampsia or asthma
  • People who are currently receiving dialysis (a treatment that filters the blood when the kidneys cannot)
  • Females under 50 years old who have a positive pregnancy test
  • People who have previously been enrolled in this trial
  • People whose treating doctor decides enrolment is not appropriate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Stephanie Sibley, MD, Queen's University

Phone: 613 549 6666

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Dr. Stephanie Sibley
Registry
ClinicalTrials.gov
Start date
20 August 2023
Est. completion
1 March 2028

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

RCT Feasibility; RCT Feasibility

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov